A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck
Robert I. Haddad(Georgetown University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Harry Raftopoulos(NewYork–Presbyterian Hospital), Murray Yule, Massimo Loda(Cornell University), Jarrod Faucher(Harvard University), Carolyn DeRosa(NewYork–Presbyterian Hospital), Tad J. Wieczorek(Brigham and Women's Hospital), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Xinxin Zhang(Dana-Farber Cancer Institute), Rosemary Costello(Dana-Farber Cancer Institute), Linda P. Miller, Nandita Bhattacharya(Dana-Farber Cancer Institute), Martin W. Oster, Vaughan M. Latham(Dana-Farber Cancer Institute), Lisa J. Weinstein(Brigham and Women's Hospital)
Cited by 67
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k